FDA发布仿制药场地自我认定指南
出自识林
FDA发布仿制药场地自我认定指南
笔记 2016-09-23 Lachman CONSULTANTS 美国FDA于9月22日发布《仿制药设施、场地和机构的自我认定》定稿指南。根据2012仿制药使用者付费修正案(GDUFA),所有仿制药设施、场地和机构必须遵循GDUFA的自我认定要求。该指南文件旨在帮助企业理解自我认定要求,从而使得自我认定更容易实现。文件还讨论了哪些设施、场地和/或机构需要支付GDUFA费用。 指南讨论了:
建立自我认定过程是为了实现以下两个目标:
该指南文件提供了简洁的描述、认定流程,并概述了在自我认定体系中必须遵循的要求。该指南也提醒我们如果企业未能自我认定,那么与该设施相关的任何产品被认为是错标冒牌的,从而会立即受到执法行动。另外,请记住,这不是一次性的过程,必须每年完成。 Lachman CONSULTANTS - Bob Pollock先生 Self-Identification Guidance for Generic Facilities Issued by FDA Under the Generic Drug User Fee Amendments (GDUFA) of 2012, all generic facilities, sites and organizations are required to comply with the self-identification requirements of the GDUFA. This Guidance document is intended to facilitate firms’ understanding of the requirements, and thus, make self-identification easier to accomplish. The document also discusses which of the facilities, sites, and or organizations will have to pay a GDUFA user fee. The Guidance discusses:
The self-identification process was established to accomplish two goals:
The Guidance document, which can be found here, provides concise descriptions, identifies processes, and outlines requirements that must be followed in the self-identification scheme. It also reminds us that if a firm fails to self-identify, any product that is associated with that establishment is considered to be misbranded, and thus, subject to immediate enforcement action. Talk about the carrot and the stick! Also remember, this is not a one-time process, and must be completed annually. 岗位必读建议:
文件适用范围: 文件要点总结:
以上仅为部分要点,请阅读原文,深入理解监管要求。 |